Analysis of EPC adoption in the pharmaceutical market
Adopting EPC in Healthcare - Cost and Benefits (Electronic Version)
2004
TBD • TBD pages
Stock #: PUBS260-E
HDMA Member: $ 25
Nonmember: $ 495
Representing the first cost analysis of EPC adoption in the pharmaceutical market, this landmark report is the only source for data on rollout steps for pharmaceutical manufacturers and distributors, complete with recommended EPC implementation timelines. HDMA commissioned Adopting EPC in Healthcare: Cost and Benefits to show actual, quantifiable economic benefits of EPC/RFID implementation. Four business cases were conducted with three manufacturers and one distributor. The results are a primary focus of this study.
Комментариев нет:
Отправить комментарий